NCT07768956Completed
Effects of Turkish Coffee and Green Tea in Fatty Liver Disease
The Effects of Turkish Coffee and Green Tea Consumption on Liver Steatosis Level and Biochemical Parameters in Individuals With Non-Alcoholic Fatty Liver Disease
Source: ClinicalTrials.gov · Last updated 17 Aug 2026
Brief summary (registry, in English)
Non-alcoholic fatty liver disease (NAFLD) is a common liver condition associated with metabolic disorders and lifestyle factors. This study aims to evaluate the effects of Turkish coffee and green tea consumption in addition to a Mediterranean diet intervention on liver fat content, biochemical parameters, and anthropometric measurements in individuals with fatty liver disease. Participants received a 12-week Mediterranean diet program and were assigned to groups consuming Turkish coffee, green tea, or no additional beverage intervention. Changes in liver ultrasonography findings, liver enzymes, metabolic parameters, and body measurements were evaluated before and after the intervention.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 47 (actual)
- First submitted
- 4 Aug 2026
- Start date
- 25 Sept 2024
- Primary completion date
- 15 Aug 2025
- Lead sponsor
- Okan University
- Diseases
- Fatty liver disease (MASLD/MASH)
- NCT number
- NCT07768956
What you commit to
- Study type: Interventional
- Participants enrolled: 47
- From 25 Sept 2024 to the primary completion date, 15 Aug 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of systemic corticosteroids or methotrexate within the previous 6 months.
- Following a dietary program within the previous month.
Other illness
- Presence of diabetes, dyslipidemia, or rheumatoid arthritis.
- Presence of liver malignancy or hepatic decompensation.
- Presence of severe psychiatric disorders.
Lab values
- Positive hepatitis B surface antigen (HBsAg), hepatitis C positivity, autoimmune hepatitis, liver cirrhosis, toxic hepatitis, or alanine aminotransferase (ALT) levels ≥10 times the upper limit of normal.
Other
- Alcohol consumption.
- Pregnancy or lactation.
- Regular use of dietary supplements.
- High daily consumption of tea and coffee.
Who the study is looking for
- Participants aged 19-65 years with a diagnosis of non-alcoholic fatty liver disease (NAFLD).
- Not using medications for diabetes, dyslipidemia, or rheumatoid arthritis.
- Not using dietary supplements.
- No dietary program followed within the previous month.
- No severe psychiatric disorders.
- Willingness to participate in the study and provide informed consent.
Age in the registry: 19 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Istanbul Dr. Lutfi Kirdar City Hospital Coordinator of this site? Confirm its status | Istanbul | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.